Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $35.1364.

Several research analysts recently commented on ROIV shares. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Guggenheim upped their price objective on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st.

Roivant Sciences Trading Up 0.1%

Shares of NASDAQ ROIV opened at $36.24 on Tuesday. The firm’s 50-day moving average price is $34.00 and its 200-day moving average price is $30.06. The stock has a market capitalization of $26.18 billion, a price-to-earnings ratio of -68.38 and a beta of 1.12. Roivant Sciences has a 12-month low of $11.54 and a 12-month high of $37.19.

Insider Buying and Selling at Roivant Sciences

In related news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the completion of the sale, the director directly owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the sale, the director owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. This trade represents a 5.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 2,055,913 shares of company stock worth $69,639,633 over the last 90 days. Company insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new stake in Roivant Sciences during the 2nd quarter valued at about $4,936,000. Great Lakes Advisors LLC bought a new position in Roivant Sciences in the 2nd quarter worth about $3,815,000. Handelsbanken Fonder AB increased its position in shares of Roivant Sciences by 51.4% during the second quarter. Handelsbanken Fonder AB now owns 177,209 shares of the company’s stock worth $6,271,000 after acquiring an additional 60,200 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Roivant Sciences by 18.2% during the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after acquiring an additional 1,286,464 shares during the period. Finally, GAMMA Investing LLC raised its position in Roivant Sciences by 17.4% during the 2nd quarter. GAMMA Investing LLC now owns 14,637 shares of the company’s stock valued at $518,000 after purchasing an additional 2,172 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.